4d agoThe FlyBEARISH 38General
Archived explainer. For the current picture see today's BEAM page.
Why Is BEAM THERAPEUTICS IN (BEAM) Stock Down Today?
By the Top Tier Newswire AI Desk · September 8, 2026 at 12:11 PM ET · reviewed against 4 wire stories
BEAM THERAPEUTICS IN (BEAM) is down -12.42% in the latest session. Our newswire has captured 4 stories on BEAM across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BEAM stock is down today
BEAM stock closed down 12.42% at $25.98 on Monday, marking a sharp reversal from a strong opening. The decline followed mixed reactions to recent clinical updates and a broader sell-off driven by insider sales and deteriorating earnings performance.
What Happened
The session began with a 4.7% gap up, as the stock opened at $31.06. This initial optimism was fueled by recent clinical updates on BEAM-302, which showed continued efficacy in treating Alpha-1 Antitrypsin Deficiency (AATD) and was highlighted at the European Respiratory Society Congress 2026. However, the positive momentum quickly reversed. By mid-morning, the stock had fallen to a session low of $25.04, closing the day at $26.00. The volume of 2.8 million shares traded was 1.4 times the 3-month average, indicating heightened investor activity.
The stock’s decline came amid a backdrop of recent insider sales, including transactions by the Chief Medical Officer and CEO, totaling $12.2 million over the last 90 days. Additionally, the company’s Q2 results showed an EPS of -$1.18, missing estimates, and revenue of $490,000, far below the projected $16.37 million.
What The Data Shows
The stock’s 52-week range is $17.74 to $38.26. On September 8, it printed one fresh 52-week high and two fresh 52-week lows. The stock has a market cap of $3.0 billion and remains unprofitable, with an EPS of -$0.84 for the trailing twelve months. Revenue has grown by 158.9% TTM, but the net margin remains at -55.4%. The stock’s beta of 2.23 indicates it is highly volatile relative to the broader market.
What To Watch
The company is scheduled to present updated clinical data for BEAM-302 at the ERS Congress 2026, which may influence investor sentiment in the near term. Coverage breadth and reactions to future data presentations will be key to watch.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BEAM by the numbers
Last: $25.98Session: -12.42%7 sessions: -11.75%Coverage: 4 stories / 2 sourcesAI sentiment: 53/100 (mixed)Mkt cap: $3.0B52w: $17.74 to $38.26
The headlines behind the move
4d agoThe FlyBEARISH 38General
Beam Therapeutics falls -12.7%
5d agoThe FlyBULLISH 67Product/PR
Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial
5d agoBusiness InsiderBULLISH 67Product/PR
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BEAM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BEAM move explainers: 2026-09-09 · 2026-09-08 · 2026-08-26 · 2026-08-25 · 2026-08-20